medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2006, Número 6

<< Anterior Siguiente >>

Rev Mex Urol 2006; 66 (6)


Consenso mexicano de salud ósea del paciente con cáncer de próstata

Jiménez RMA, Aragón TAR, Carvajal GR, Chan NCA, Cortés BR, Silva GA, Hernández TN, Farías MA, Flores GA, Hinojosa GJ, Nolasco MR, Serrano BE, Solares SME, Tokunaga FJ

Idioma: Español
Referencias bibliográficas: 39
Paginas: 283-297
Archivo PDF: 219.12 Kb.


RESUMEN

Un grupo de especialistas mexicanos, expertos en el tratamiento del cáncer de próstata, identificaron la necesidad de uniformar los criterios de complicaciones óseas relacionadas con dicho padecimiento. Con el objetivo de ofrecer recomendaciones a la comunidad médica nacional, sobre el manejo eficaz y uniforme de la salud ósea del paciente con cáncer de próstata, llevaron a cabo una reunión de consenso, de la que emanó el presente documento.
El presente trabajo ofrece una visión comprehensiva de la enfermedad, destacando los aspectos epidemiológicos, la historia natural del padecimiento, la fisiología del recambio óseo y de las metástasis óseas, además del impacto económico y social de esta complicación. Los lineamientos sugieren criterios de prevención de las metástasis óseas, así como su manejo hormonal, médico y radioterapéutico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McKiernan y col. Proc Am Soc Clin Oncol. 2004. Abstract 6057.

  2. Dacal K, Sereika S, Greenspan S. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Ger Soc. 2006;54:85-90.

  3. Registro Histopatológico de Neoplasias Malignas en México. 2002. Dirección General de Epidemiología.

  4. Hortobagyi G. Progress in the management of bone metastases: one continent at time? J Clin Oncol. 2005;23:1-3.

  5. Abrahamsson P. Pathophysiology of bone metastases in prostate cancer. Eur Urol. Suppl 2004;3:3-9.

  6. Crawford D. Skeletal complications in men with prostate cancer: effects on quality of life outcomes throughout the continuum of care. Eur Urol. Suppl 2004;3:10-15.

  7. Brown JE. The role of bisphosphonates in breast and prostate cancers. Endocrine-Related Cancer. 2004; 11:207-224.

  8. Green J. Preclinical profile of zoledronic acid in prostate cancer models. Eur Urol. Suppl 2004;3:16-24.

  9. Berenson JR. Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases. The Oncologist. 2005;10:52-62.

  10. Lothorlary MA, Hon J, Abdi E y col. Zoledronic Acid is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy : A pooled Analysis of Randomized, Controlled Clinical Trials. J Clin Oncol. 2001 ;19 :558-567.

  11. Jiménez M, Moreno J, Ochoa F y col. Consenso Mexicano sobre manejo de metástasis óseas en cáncer de próstata. Revista Mexicana de Urología. 2005;65:7-24.

  12. Saad F, Gleason DM y col. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96:879-82.

  13. Saad F. Preventing bone complications in patients with prostate cancer: the emerging role of zoledronic acid. Eur Urol. Suppl 2004;3:25-33.

  14. Carroll P, Altwein J, Brawley O y col. Management of disseminated prostate cancer. In: Denis L, Bartsch G, Khoury S y col. Prostate Cancer: 3rd International.

  15. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646.

  16. Smith MR. Therapy insight: osteoporosis during hormone therapy for prostate cancer. Nature Clinical Practice Urology. 2005;2:608-615.

  17. Bae D, Stein B. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol. 2004;172:2137-2144.

  18. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin N Am. 2004;31:331-352.

  19. Intensifica el ISSSTE campaña para el diagnóstico oportuno de hiperplasia y cáncer de próstata. 040606/ Fuente ISSSTE. B.160-2004. México, Gobierno de la República. http://envivo.presidencia.gob.mx/P=42& Orden=Leer&Tipo=&Art=8338

  20. Moul J, Krupski T, Smith M. Managing bone complications in Prostate Cancer. American Urological Association Education and Research, Inc. Annual Meeting 2005. San Antonio, Tx.

  21. Grupo Medicina Basada en Evidencias de Galicia, España. Osteoporosis. Guías Clínicas. 2003;3(24).

  22. Iqbal MM. Osteoporosis: Epidemiology, Diagnosis, and Treatment. http://www.medscape.com/viewarticle/ 410461_print.

  23. Brown JE, Cook RJ, Major P y col. Bone turnover as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59-69.

  24. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, version 2.0, IARCPress, Lyon. 2004.

  25. Matthew RS, Won Chan Lee y col. Gonadotropin-releasing hormone agonist and fracture risk: a claimbased cohort study of men with nonmetastatic prostate cancer. JCO. 2005;31.

  26. Morote J, Martinez E, Trilla E y col. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol. 2003;44:661-665.

  27. Greenspan SL, Penelope C, Sereika S y col. Bone loss after initiation of androgen therapy in patients with prostate cancer. J Cl Endocrinol Metabol. 2005;90: 6410-6417.

  28. Tracey L. Krupski, Matthew R Smith, Won Chan Lee y col. Natural History of Bone Complications in Men with Prostate Carcinoma Initiating Androgen Deprivation Therapy. Cancer. 2004;101:541-48.

  29. Lindsay R, Cosman F. Osteoporosis. Chapter 333. pp: 2268-78. Harrison’s Principles of Internal Medicine, 16th Edition, 2005.

  30. Smith M y col. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for non metastatic prostate cancer. J Urol. 2003;169:2008-2012.

  31. Reid I y col. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;28:653-661.

  32. Stock J, Bell N y col. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med. 1997;103:291-7.

  33. Manoso MW, Healey JH. “Chapter 51:Treatment of metastatic cancer. Metastatic Cancer to the Bone” Cancer Principles & Practice of Oncology 7th Edition Vincent T DeVita. Lippincott Williams & Wilkins 2005: 2368-2381.

  34. Ratanatharathorn V. “Chapter 87: Palliation of Bone Metastases” in C. Perez Principles and Practice of Radiation Oncology 4th Ed, Lippincott Williams & Wilkins 2004: 2385-2404.

  35. Arcangeli G. Radiation therapy in the management of symptomatic bone metastases: The effect of total dose and histology on pain relief and response duration. IJROBP. 1998;42:119-1126.

  36. Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastases from prostate cancer. IJROBP. 2004;60:1373-1378.

  37. Singh D. Is there a favorable subset of patients with prostate cancer who develop oligometastases. IJROBP. 2004;58:3-10.

  38. Schechter NR. Chap 34. The Bone in Radiation Oncology. JD Cox. 8th Edition Mosby 2003:857-883.

  39. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev. 2001;27:187-92; discussion 193-6.




2020     |     www.medigraphic.com